ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, will attend the eighth annual International Strategy and Investment (ISI) Group’s MedTools and Outsourcing Investor Forum. The forum will take place Dec. 3-4 at the Boston Harbor Hotel, where leading companies from the life science tools, diagnostics and contract research organization (CRO) markets will have the opportunity to meet with key institutional investors.
“The MedTools and Outsourcing Investor Forum is a key venue for Rheonix to inform and educate attending investors on the opportunity to invest in Rheonix to bring powerful molecular tools to market that will benefit patients, physicians and laboratories worldwide. The Evercore ISI group is highly informed and connected in the medical technology market. They have the ability to connect companies with unique and disruptive technologies, such as Rheonix, with financial institutions and companies that have the capital to help bring these tools to market,” Steve Pemberton, vice president of marketing and sales, Rheonix.
The conference comprises a series of small-group and one-on-one meetings with key institutional investors, with each session lasting 45 minutes. The forum typically attracts over 100 investors, analysts and portfolio managers.
Rheonix will discuss its innovative platform, the EncompassMDx™ . The EncompassMDx is a platform with unmatched versatility and affordability that performs fully automated, complex molecular assays in an easy-to-use and economical format using the Rheonix CARD® cartridge. The CARD is a cartridge the size of a smartphone that can run several biological samples through a fully integrated molecular analysis with no user intervention—it automatically manipulates the network of microfluidic pumps, valves and channels. The EncompassMDx can dramatically decrease the cost of testing, while increasing user efficiency and accuracy. Furthermore, the product’s automation, capability for high throughput and high complexity, and unique sample-to-result system will allow the platform to solve workflow inefficiencies within the diagnostic segment of the health care industry.
The company was recently granted patent 8,852,919, “Microfluidic Apparatus, Method, and Applications,” a breakthrough innovation that utilizes a proprietary liquid-liquid extraction methodology for automated preparation of paraffin-preserved tissue samples for nucleic acid analysis. The patent, in conjunction with the CARD cartridge, will help researchers, clinicians and scientists analyze the enormous backlog of tissue samples preserved in paraffin.
For more information, visit www.rheonix.com.